Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | STAMPEDE: updates in evaluating tE2 patches with ARPIs in prostate cancer

Nicholas James • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer
STAMPEDE

Nicholas James, MBBS, PhD, FRCP, FRCR, Institute of Cancer Research, London, UK, explores findings from the Phase II STAMPEDE trial (NCT00268476) of transdermal estradiol (tE2) patches versus luteinising hormone releasing hormone analogues (LHRHa) when combined with androgen receptor pathway inhibitors (ARPIs) in metastatic prostate cancer. PSA responses were similar between groups, supporting tE2 as a viable alternative for androgen deprivation therapy. Notably, tE2 was associated with fewer hot flushes and lower hypertension rates, providing an alternative toxicity profile that may improve patient quality of life. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicholas James

What are the advantages of ADT transdermal patches for prostate cancer?
1:23
What are the advantages of ADT transdermal patches for prostate cancer?
Nicholas James • 13 Feb 2025
RAD-IO: assessing the feasibility of durvalumab with CRT in bladder cancer
2:01
RAD-IO: assessing the feasibility of durvalumab with CRT in bladder cancer
Nicholas James • 13 Feb 2025
Novel pilot schemes to increase prostate cancer screening rates in Nigeria
2:09
Novel pilot schemes to increase prostate cancer screening rates in Nigeria
Nicholas James • 22 Apr 2024
Findings from the Lancet Commission on prostate cancer
4:38
Findings from the Lancet Commission on prostate cancer
Nicholas James • 22 Apr 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals